Goldman Sachs
HAE icon

Goldman Sachs’s Haemonetics HAE Stock Holding History

Goldman Sachs’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$868K Buy
+15,400
New +$1M ﹤0.01% 5191

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs's HAE Position: Q1 2026 in Review

Goldman Sachs reduced its Haemonetics (HAE) stake by 22% in Q1 2026, selling an estimated $17.8M and leaving 952,820 shares worth $53.7M. The position accounts for 0.01% of the portfolio, ranked #1522.

Goldman Sachs first reported a position in HAE in Q2 2013 and has held it in 52 quarters since. The position peaked at $98.3M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Goldman Sachs held 952,820 shares of Haemonetics worth $53.7M as of Q1 2026.
  • Goldman Sachs sold 273,794 Haemonetics shares in Q1 2026, an estimated $17.8M.
  • Haemonetics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1522 holding.
  • Goldman Sachs first reported a position in Haemonetics in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Haemonetics position peaked at $98.3M in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.